Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
RM Shallis, R Wang, A Davidoff, X Ma, AM Zeidan - Blood reviews, 2019 - Elsevier
Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …
Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets
Abstract Purpose of Review Immune checkpoint therapy has dramatically changed the
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …
Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies
L Handschuh - Journal of oncology, 2019 - Wiley Online Library
The last two decades of genome‐scale research revealed a complex molecular picture of
acute myeloid leukemia (AML). On the one hand, a number of mutations were discovered …
acute myeloid leukemia (AML). On the one hand, a number of mutations were discovered …
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Epigenetics refers to the regulation of gene expression mainly by changes in DNA
methylation and modifications of histone proteins without altering the actual DNA sequence …
methylation and modifications of histone proteins without altering the actual DNA sequence …
Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
The 5-year overall survival rate of AML patients remains 25–40%. The prognosis is even
more dismal for older patients who are ineligible for intensive chemotherapy and patients …
more dismal for older patients who are ineligible for intensive chemotherapy and patients …
The immune checkpoints cytotoxic T lymphocyte antigen‐4 and Lymphocyte activation gene‐3 expression is up‐regulated in acute myeloid leukemia
One of the fundamental hallmarks of cancer is the incapacity of the immune system to
eliminate malignancy. Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and lymphocyte …
eliminate malignancy. Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and lymphocyte …
Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
N Vey - Therapeutic advances in hematology, 2020 - journals.sagepub.com
Treatment options for elderly patients with acute myeloid leukemia (AML) remain limited. In
this age group, AML is frequently associated with poor-risk features, while patients' present …
this age group, AML is frequently associated with poor-risk features, while patients' present …
Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome
Despite recent advancements in the therapeutic landscape of acute myeloid leukemia
(AML), the prognosis of patients remains poor. Immune check point inhibitors have been …
(AML), the prognosis of patients remains poor. Immune check point inhibitors have been …
Comparison of the kinase profile of midostaurin (Rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to …
PW Manley, G Caravatti, P Furet, J Roesel, P Tran… - Biochemistry, 2018 - ACS Publications
The multitargeted protein kinase inhibitor midostaurin is approved for the treatment of both
newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and KIT-driven advanced …
newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and KIT-driven advanced …